Literature DB >> 30225619

Young age at diagnosis is associated with worse prognosis in the Luminal A breast cancer subtype: a retrospective institutional cohort study.

Zhiyang Liu1,2, Zeyad Sahli2, Yongchun Wang2, Antonio C Wolff3, Leslie M Cope4, Christopher B Umbricht5.   

Abstract

PURPOSE: Although age is a recognized independent prognostic risk factor, its relative importance among molecular subtypes of Breast cancer (BCA) is not well documented. The aim of this study was to evaluate the prognostic role of age at diagnosis among different immunohistochemical subtypes of BCA.
METHODS: We conducted a retrospective study of women with invasive BCA undergoing surgery at the Johns Hopkins Hospital, excluding patients presenting with stage IV breast cancer. Patients were stratified into three age groups: ≤ 40, 41-60, and > 60 years, and multivariable analysis was performed using Cox regression. We also identified differentially expressed genes (DEG) between age groups among BCA subtypes in the public TCGA dataset. Finally, we identified key driver genes within the DEGs using a weighted gene co-expression network analysis.
RESULTS: Luminal A breast cancer patients had significantly lower 5 year disease-free survival (DFS) and distant metastasis-free survival (DMFS) in the ≤ 40 year age group compared to the 41-60 year age group, while the other molecular subtypes showed no significant association of DFS or DMFS with age. Age was a stronger outcome predictor than tumor grade or proliferative index in Luminal A BCA patients, but not other subtypes. BCA TCGA gene expression data were divided into two groups (≤ 40 years, > 40 years). We identified 374 DEGs in the Luminal A BCA subset, which were enriched in seven pathways and two modules of co-expressed genes. No age group-specific DEGs were identified in non-Luminal A subtypes.
CONCLUSIONS: Age at diagnosis may be an important prognostic factor in Luminal A BCA.

Entities:  

Keywords:  Age; Breast cancer; Gene expression; Intrinsic subtype; Prognosis

Mesh:

Substances:

Year:  2018        PMID: 30225619      PMCID: PMC6786966          DOI: 10.1007/s10549-018-4950-4

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  46 in total

1.  Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer.

Authors:  Willemien van de Water; Christos Markopoulos; Cornelis J H van de Velde; Caroline Seynaeve; Annette Hasenburg; Daniel Rea; Hein Putter; Johan W R Nortier; Anton J M de Craen; Elysée T M Hille; Esther Bastiaannet; Peyman Hadji; Rudi G J Westendorp; Gerrit-Jan Liefers; Stephen E Jones
Journal:  JAMA       Date:  2012-02-08       Impact factor: 56.272

2.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

3.  Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases.

Authors:  C L Carter; C Allen; D E Henson
Journal:  Cancer       Date:  1989-01-01       Impact factor: 6.860

4.  Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival.

Authors:  Ann H Partridge; Melissa E Hughes; Erica T Warner; Rebecca A Ottesen; Yu-Ning Wong; Stephen B Edge; Richard L Theriault; Douglas W Blayney; Joyce C Niland; Eric P Winer; Jane C Weeks; Rulla M Tamimi
Journal:  J Clin Oncol       Date:  2016-08-01       Impact factor: 44.544

5.  Comorbidity and survival disparities among black and white patients with breast cancer.

Authors:  C Martin Tammemagi; David Nerenz; Christine Neslund-Dudas; Carolyn Feldkamp; David Nathanson
Journal:  JAMA       Date:  2005-10-12       Impact factor: 56.272

6.  Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.

Authors:  Poornima Saha; Meredith M Regan; Olivia Pagani; Prudence A Francis; Barbara A Walley; Karin Ribi; Jürg Bernhard; Weixiu Luo; Henry L Gómez; Harold J Burstein; Vani Parmar; Roberto Torres; Josephine Stewart; Meritxell Bellet; Antonia Perelló; Faysal Dane; Antonio Moreira; Daniel Vorobiof; Michelle Nottage; Karen N Price; Alan S Coates; Aron Goldhirsch; Richard D Gelber; Marco Colleoni; Gini F Fleming
Journal:  J Clin Oncol       Date:  2017-06-27       Impact factor: 44.544

Review 7.  Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer.

Authors:  Evette S Radisky; Derek C Radisky
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-05-05       Impact factor: 2.673

8.  The influence of young age on outcome in early stage breast cancer.

Authors:  B L Fowble; D J Schultz; B Overmoyer; L J Solin; K Fox; L Jardines; S Orel; J H Glick
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-08-30       Impact factor: 7.038

9.  Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens.

Authors:  José Alejandro Pérez-Fidalgo; Susana Roselló; Elisa García-Garré; Esther Jordá; Paloma Martín-Martorell; Begoña Bermejo; Isabel Chirivella; Cecilia Guzman; Ana Lluch
Journal:  Breast Cancer Res Treat       Date:  2009-07-03       Impact factor: 4.872

10.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

Authors:  Antonio C Wolff; M Elizabeth Hale Hammond; Kimberly H Allison; Brittany E Harvey; Pamela B Mangu; John M S Bartlett; Michael Bilous; Ian O Ellis; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Lisa M McShane; Mitchell Dowsett
Journal:  Arch Pathol Lab Med       Date:  2018-05-30       Impact factor: 5.686

View more
  11 in total

1.  Refining breast cancer prognosis by incorporating age at diagnosis into clinical prognostic staging: introduction of a novel online calculator.

Authors:  Helen M Johnson; William Irish; Nasreen A Vohra; Jan H Wong
Journal:  Breast Cancer Res Treat       Date:  2021-02-20       Impact factor: 4.872

2.  Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer.

Authors:  Ann H Partridge; Laura C Collins; Yaileen D Guzmán-Arocho; Shoshana M Rosenberg; Judy E Garber; Hilde Vardeh; Philip D Poorvu; Kathryn J Ruddy; Gregory Kirkner; Craig Snow; Rulla M Tamimi; Jeffrey Peppercorn; Lidia Schapira; Virginia F Borges; Steven E Come; Elena F Brachtel; Jonathan D Marotti; Ellen Warner
Journal:  Br J Cancer       Date:  2021-10-26       Impact factor: 7.640

3.  Comparing the Prognoses of Breast-Conserving Surgeries for Differently Aged Women with Early Stage Breast Cancer: Use of a Propensity Score Method.

Authors:  Shurui Bao; Guijin He
Journal:  Breast J       Date:  2022-04-23       Impact factor: 2.269

4.  SIRT7 Is a Prognostic Biomarker Associated With Immune Infiltration in Luminal Breast Cancer.

Authors:  Qin Huo; Zhenwei Li; Lixin Cheng; Fan Yang; Ni Xie
Journal:  Front Oncol       Date:  2020-05-12       Impact factor: 6.244

5.  Real-world, single-centre prospective data of age at breast cancer onset: focus on survival and reproductive history.

Authors:  Peeter Karihtala; Anniina Jääskeläinen; Nelli Roininen; Arja Jukkola
Journal:  BMJ Open       Date:  2021-01-31       Impact factor: 2.692

6.  Estrogen Receptor and Claudin-6 Might Play Vital Roles for Long-Term Prognosis in Patients With Luminal A Breast Cancer Who Underwent Neoadjuvant Chemotherapy.

Authors:  Yushi Liu; Ye Kang; Jianyi Li; Yang Zhang; Shi Jia; Qiang Sun; Yan Ma; Jing Zhang; Zhenrong Wang; Yanan Cao; Yang Shen
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

7.  Effect of Previous Cancer History on Survival of Patients with Different Subtypes of Breast Cancer.

Authors:  Weixun Lin; Yaokun Chen; Zeqi Ji; Lingzhi Chen; Jinyao Wu; Yexi Chen; Zhiyang Li
Journal:  Biomed Res Int       Date:  2022-09-02       Impact factor: 3.246

8.  Young age at diagnosis is associated with better prognosis in stage IV breast cancer.

Authors:  Wei Liu; Xi-Feng Xiong; Yu-Zhen Mo; Wei-Guang Chen; Mei Li; Rong Liang; Zhi-Biao Zhang; Zhi Zhang
Journal:  Aging (Albany NY)       Date:  2019-12-11       Impact factor: 5.682

Review 9.  Association of folate intake and plasma folate level with the risk of breast cancer: a dose-response meta-analysis of observational studies.

Authors:  Xueting Ren; Peng Xu; Dai Zhang; Kang Liu; Dingli Song; Yi Zheng; Si Yang; Na Li; Qian Hao; Ying Wu; Zhen Zhai; Huafeng Kang; Zhijun Dai
Journal:  Aging (Albany NY)       Date:  2020-11-04       Impact factor: 5.682

10.  No Excess Mortality up to 10 Years in Early Stages of Breast Cancer in Women Adherent to Oral Endocrine Therapy: A Probabilistic Graphical Modeling Approach.

Authors:  Ramon Clèries; Maria Buxó; Mireia Vilardell; Alberto Ameijide; José Miguel Martínez; Rebeca Font; Rafael Marcos-Gragera; Montse Puigdemont; Gemma Viñas; Marià Carulla; Josep Alfons Espinàs; Jaume Galceran; Ángel Izquierdo; Josep Maria Borràs
Journal:  Int J Environ Res Public Health       Date:  2022-03-18       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.